XTL Other Non Cash Items vs End Period Cash Flow Analysis
| XTLB Stock | USD 2.10 0.22 11.70% |
XTL Biopharmaceutica financial indicator trend analysis is more than just analyzing XTL Biopharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether XTL Biopharmaceuticals is a good investment. Please check the relationship between XTL Biopharmaceutica Other Non Cash Items and its End Period Cash Flow accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Other Non Cash Items vs End Period Cash Flow
Other Non Cash Items vs End Period Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of XTL Biopharmaceuticals Other Non Cash Items account and End Period Cash Flow. At this time, the significance of the direction appears to have no relationship.
The correlation between XTL Biopharmaceutica's Other Non Cash Items and End Period Cash Flow is 0.04. Overlapping area represents the amount of variation of Other Non Cash Items that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of XTL Biopharmaceuticals Ltd, assuming nothing else is changed. The correlation between historical values of XTL Biopharmaceutica's Other Non Cash Items and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Non Cash Items of XTL Biopharmaceuticals Ltd are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Other Non Cash Items i.e., XTL Biopharmaceutica's Other Non Cash Items and End Period Cash Flow go up and down completely randomly.
Correlation Coefficient | 0.04 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Other Non Cash Items
End Period Cash Flow
Most indicators from XTL Biopharmaceutica's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into XTL Biopharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At present, XTL Biopharmaceutica's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 3.9 M, whereas Selling General Administrative is forecasted to decline to about 697.3 K.
XTL Biopharmaceutica fundamental ratios Correlations
Click cells to compare fundamentals
XTL Biopharmaceutica Account Relationship Matchups
High Positive Relationship
High Negative Relationship
XTL Biopharmaceutica fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 7.2M | 6.5M | 6.6M | 4.2M | 2.4M | 2.3M | |
| Total Stockholder Equity | 7.0M | 6.2M | 5.3M | 4.0M | 2.2M | 2.1M | |
| Common Stock Shares Outstanding | 5.1M | 514.2M | 615.5M | 544.9M | 544.9M | 572.2M | |
| Liabilities And Stockholders Equity | 7.2M | 6.5M | 6.6M | 4.2M | 2.4M | 2.3M | |
| Total Liab | 232K | 254K | 1.3M | 187K | 206K | 195.7K | |
| Other Current Liab | 231K | 252K | 229K | 185K | 205K | 194.8K | |
| Total Current Liabilities | 232K | 254K | 231K | 187K | 206K | 195.7K | |
| Other Liab | 1.0M | 465K | 2.6M | 1.1M | 1.2M | 1.3M | |
| Net Debt | (4.5M) | (3.6M) | (3.0M) | (2.1M) | (1.4M) | (1.5M) | |
| Retained Earnings | (153.9M) | (154.7M) | (155.1M) | (156.5M) | (158.2M) | (166.2M) | |
| Cash | 4.5M | 3.6M | 3.0M | 2.1M | 1.4M | 1.3M | |
| Cash And Short Term Investments | 6.7M | 6.0M | 6.1M | 3.7M | 2.0M | 1.9M | |
| Short Term Investments | 2.3M | 2.4M | 3.2M | 1.6M | 605K | 574.8K | |
| Non Current Liabilities Total | 2.7M | 0.0 | 1K | 2.6M | 1.1M | 2K | |
| Other Current Assets | 102K | 79K | 110K | 85K | 40K | 68K | |
| Total Current Assets | 6.8M | 6.1M | 6.2M | 3.8M | 2.0M | 1.9M | |
| Net Tangible Assets | 6.6M | 3.2M | 5.0M | 3.6M | 4.2M | 4.6M | |
| Net Invested Capital | 7.0M | 6.2M | 5.3M | 4.0M | 2.2M | 4.2M | |
| Net Working Capital | 6.6M | 5.9M | 6.0M | 3.6M | 1.8M | 1.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.03) | Return On Assets (0.14) | Return On Equity (0.13) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.